The use of systemic antimycotics in dermatotherapy

European Journal of Dermatology

Volumn 10, Issue 2, 2000, Pages 155-160

  Niewerth, Markus ^a   Korting, Hans C ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Fluconazole; Itraconazole; Onychomycosis; Systemic antimycotics; Terbinafine; Tinea

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; BIFONAZOLE; CICLOPIROXOLAMINE; CLOTRIMAZOLE; ECONAZOLE; FLUCONAZOLE; GRISEOFULVIN; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NAFTIFINE; SERTACONAZOLE; TERBINAFINE;

DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; ONYCHOMYCOSIS; PRURITUS; RASH; SHORT SURVEY; TINEA; VERTIGO;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; COST-BENEFIT ANALYSIS; DERMATOMYCOSES; FLUCONAZOLE; GRISEOFULVIN; HAIR DISEASES; HUMANS; ITRACONAZOLE; KETOCONAZOLE; NAPHTHALENES; ODDS RATIO; ONYCHOMYCOSIS; TINEA;

EID: 0033998482     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (25)

1. 1. Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 1994; 31: S21-5.
2. 2. Williams HC. The epidemiology of onychomycosis in Britain. Br J Dermatol 1993; 129: 101-9.
3. 3. Drake LA, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998; 38: 702-4.
4. 4. Meinhof W. Isolierung und Identifizierung von Dermatophyten (in German). Zbl Bakt 1990; 273: 229-45.
5. 5. Korting HC, Ollert M, Abeck D. Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. Antimicrob Agents Chemother 1995; 39: 1206-8.
6. 6. Elewski B, Bergstresser PR, Hanifin J, et al. Long-term outcome of patients with interdigital tinea pedis treated with terbinafine or clotrimazole. J Am Acad Dermatol 1995; 32: 290-2.
7. 7. Alomar C et al.. Multi-centre double-blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses. Drug Res 1992; 42: 767-71.
8. 8. Korting HC, Klövekorn W, Klövekorn G. Comparative efficacy and tolerability of econazole liposomal gel 1%, branded econazole conventional cream 1% and generic clotrimazole cream 1% in tinea pedis. Clin Drug Invest 1997; 14: 286-93.
9. 9. Abeck D, Gruseck E, Korting HC, Ring J. Onychomykose: Epidemiologie, Pathogenese, Klinik, Mikrobiologie und Therapie (in German). Dt Ärztebl 1996; 93: A-2027-32.
10. 10. Schäfer-Korting M, Korting HC, Mutschler E. Human plasma and skin blister fluid levels of griseofulvin after its repeated administration. Eur J Clin Pharmacol 1985; 29: 351-4.
11. 11. Korting HC, Schäfer-Korting M. Is tinea unguium still widely incurable? Arch Dermatol 1992; 128: 243-8.
12. 12. Haria M, Bryson HM, Goa KL. Itraconazole: a reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996; 51: 585-620.
13. 13. Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18: 263-8.
14. 14. Willemsen N, De Doncker P, Willems J. Posttreatment itraconazole levels in nail. New implications for the treatment of onychomycosis. J Am Acad Dermatol 1992; 26: 731-5.
15. 15. Niewerth M, Splanemann V, Korting HC, et al. Antimicrobial susceptibility testing of dermatophytes - comparison of the agar macrodilution and broth microdilution tests. Chemotherapy 1998; 44: 31-5.
16. 16. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259-84.
17. 17. Gupta AK, Shear NH. Terbinafine: an update. J Am Acad Dermatol. 1997; 37: 979-88.
18. 18. Smith SW, Sealy DP, Schneider E, et al. An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis. Southern Med J 1995; 88: 1217-20.
19. 19. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39: 877-916.
20. 20. Wildfeuer A, Faergemann J, Laufen H, et al. Bioavailability of fluconazole in the skin after oral medication. Mycoses 1994; 37: 127-30.
21. 21. Scher RK. A placebo-controlled randomized, double-blind trial of once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. 37th ICAAC, Toronto, Ontario, Canada, 1997, September 28-October 1.
22. 22. Rote Liste 1998 (in German). Aulendorf: Editio Cantor, 1998: 21.001-148.
23. 23. Süss R, Korting HC. Generalised pustular drug rash. Eur J Dermatol 1994; 5: 351-3.
24. 24. Gupta AK, De Doncker P, Heenen M. An overview and assessment of the use of the antifungal agents itraconazole, terbinafine, and fluconazole in dermatology. In: Korting HC, Schäfer-Korting M, eds. The benefit/risk ratio. Boca Raton: CRC Press LLC, 1999: 263-85.
25. 25. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994; 30: 911-33.